Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 16, Issue 4, Pages 987-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2007.07.003
Keywords
-
Funding
- NINDS NIH HHS [K08 NS 046430, K08 NS046430-03, K08 NS046430] Funding Source: Medline
Ask authors/readers for more resources
Immunotherapy has emerged as a promising tool in the management of malignant central nervous system tumors. Despite improvement in patient survival, traditional approaches, which consist mostly of surgery, radiotherapy, and chemotherapy, have been largely unsuccessful in permanently controlling these aggressive tumors. Immunotherapeutic strategies offer not only a novel approach but also an advantage in a way other modalities have been failing. Specifically, the capabilities of the immune system to recognize altered cells while leaving normal cells intact offer tremendous advantage over the conventional therapeutic approaches. This article summarizes our current understanding of immunotherapeutic treatment modalities used in clinical trials for management of malignant central nervous system tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available